Carbonic anhydrase IX in oligodendroglial brain tumors
1 Department of Pathology, Centre for Laboratory Medicine, Tampere University Hospital, Tampere, Finland
2 Institute of Medical Technology, University of Tampere and Tampere University Hospital, Tampere, Finland
3 Department of Genetics, Centre for Laboratory Medicine, Tampere University Hospital, Tampere, Finland
4 Department of Neurology, Tampere University Hospital, Tampere, Finland
5 Department of Pathology, University of Oulu, Oulu, Finland
6 Centre of Molecular Medicine, Institute of Virology, Slovak Academy of Sciences, Slovak Republic
BMC Cancer 2008, 8:1 doi:10.1186/1471-2407-8-1Published: 4 January 2008
Carbonic anhydrase IX is a hypoxia-induced enzyme that has many biologically important functions, including its role in cell adhesion and invasion.
This study was set out to investigate the role of CA IX in a series of 86 oligodendroglial brain tumors (71 primary and 15 recurrent; 48 pure oligodendrogliomas and 40 mixed oligoastrocytomas).
80% of the tumors showed CA IX expression by immunohistochemistry. Tumors with moderate or strong CA IX expression had decreased level of cell proliferation compared to weak or no CA IX expression (median 2.9 vs. 5.8, p = 0.015). CA IX correlated with two antioxidative enzymes, manganese superoxide dismutase (MnSOD) and regulatory gammaglutamylcysteine synthetase (GLCL-R): CA IX expression was significantly higher in MnSOD-positive tumors (p = 0.008) and decreased in GLCL-R-positive tumors (p = 0.044). In Cox multivariate analysis CA IX expression, patient age and histological component (pure oligodendroglioma vs. mixed oligoastrocytoma) showed independent prognostic values (p = 0.009, p = 0.003 and p = 0.022, respectively), CA IX positivity predicting poorer outcome.
CA IX was proved to be an independent prognostic indicator in oligodendroglial brain tumors, and it also correlates reversely with cell proliferation. It may have a role in the biology of oligodendrogliomas, and most interestingly, as it is mainly expressed in tumor tissue, CA IX could serve as a target molecule for anticancer treatments.